The present invention provides novel CD47 antibodies or immunologically activefragments thereof that have low immunogenicity in humans and cause low or nolevel of redblood cell depletion or hemagglutination, as well as pharmaceuticalcompositions containingsuch antibodies that can be used for treatment diseases mediated by CD47 orinhibition ofphagocytosis or platelet aggregation.